Matrix metalloproteinase-1 peptide-HLA complex (MMP1-HLA) (MMP1-HLA)

The Matrix metalloproteinase-1 (MMP1) peptide-HLA complex is a tumor-associated antigen (TAA) formed by the presentation of MMP1-derived peptides on the cell surface via Human Leukocyte Antigen (HLA) molecules (Kim et al., 2004; PubMed: 15150594). MMP1, also known as interstitial collagenase, is a zinc-dependent endopeptidase that degrades collagen types I, II, and III, facilitating extracellular matrix remodeling (UniProt P03956). In many cancers, including lung, breast, and melanoma, MMP1 is significantly overexpressed and correlates with increased tumor invasiveness and poor prognosis (PubMed: 22532582). The complex, particularly when involving the HLA-A*02:01 allele, serves as a specific target for immunotherapeutic interventions such as T-cell receptor (TCR) engineered T cells and peptide-based vaccines (PubMed: 15150594). These therapies aim to exploit the differential expression of MMP1 between malignant and healthy tissues to induce a targeted cytotoxic T-lymphocyte (CTL) response. However, therapeutic development must account for potential safety concerns, such as on-target off-tumor toxicity in tissues undergoing active physiological remodeling or wound healing where MMP1 is naturally expressed (PubMed: 12124337). Furthermore, the high degree of homology between different matrix metalloproteinases necessitates rigorous testing for TCR cross-reactivity to ensure specificity.

Other names

MMP1-derived peptide-MHC complexInterstitial collagenase peptide-HLA complexMMP1/HLA-A*02:01 complexMMP1-MHC complex

T-cell receptor (TCR) mediated recognition of the peptide-HLA complex leading to cytotoxic T-lymphocyte (CTL) activation and tumor cell lysis.